P2RX7 Gene

Migration, Crosslink

📖

P2RX7 Gene

active

wiki page Created: 2026-04-02T07:19:24 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-p2rx7

📖 Wiki Page

gene2363 wordssynced 2026-04-02

P2RX7 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">p2rx7</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>P2RX7</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Purinergic Receptor P2X Ligand-Gated Ion Channel 7</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>12</td>
</tr>
<tr>
<td class="label">Genomic Location</td>
<td>12q24.31</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10278</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>601636</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000088038</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q99572</td>
</tr>
<tr>
<td class="label">EC50 for ATP</td>
<td>~100-300 μM (much higher than other P2X receptors)</td>
</tr>
<tr>
<td class="label">Agonists</td>
<td>ATP, BzATP (more potent), dibutyryl-cAMP</td>
</tr>
<tr>
<td class="label">Antagonists</td>
<td>Brilliant Blue G, KN-62, A-438079, AZD9056</td>
</tr>
<tr>
<td class="label">Allosteric modulators</td>
<td>Zinc (potentiator), Copper (inhibitor), pH effects</td>
</tr>
<tr>
<td class="label">Ion selectivity</td>
<td>Non-selective for cations, impermeable to anions</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">AZD9056</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td class="label">GSK-1482160</td>
<td>GSK</td>
</tr>
<tr>
<td

...

P2RX7 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">p2rx7</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>P2RX7</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Purinergic Receptor P2X Ligand-Gated Ion Channel 7</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>12</td>
</tr>
<tr>
<td class="label">Genomic Location</td>
<td>12q24.31</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10278</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>601636</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000088038</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q99572</td>
</tr>
<tr>
<td class="label">EC50 for ATP</td>
<td>~100-300 μM (much higher than other P2X receptors)</td>
</tr>
<tr>
<td class="label">Agonists</td>
<td>ATP, BzATP (more potent), dibutyryl-cAMP</td>
</tr>
<tr>
<td class="label">Antagonists</td>
<td>Brilliant Blue G, KN-62, A-438079, AZD9056</td>
</tr>
<tr>
<td class="label">Allosteric modulators</td>
<td>Zinc (potentiator), Copper (inhibitor), pH effects</td>
</tr>
<tr>
<td class="label">Ion selectivity</td>
<td>Non-selective for cations, impermeable to anions</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">AZD9056</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td class="label">GSK-1482160</td>
<td>GSK</td>
</tr>
<tr>
<td class="label">A-438079</td>
<td>Pfizer</td>
</tr>
<tr>
<td class="label">JNJ-47965567</td>
<td>Janssen</td>
</tr>
<tr>
<td class="label">Year</td>
<td>Milestone</td>
</tr>
<tr>
<td class="label">1996</td>
<td>P2X7 cloning</td>
</tr>
<tr>
<td class="label">1999</td>
<td>Inflammasome link</td>
</tr>
<tr>
<td class="label">2004</td>
<td>P2X7 in AD</td>
</tr>
<tr>
<td class="label">2006</td>
<td>Knockout mice</td>
</tr>
<tr>
<td class="label">2012</td>
<td>Crystallography</td>
</tr>
<tr>
<td class="label">2015</td>
<td>Clinical trials</td>
</tr>
<tr>
<td class="label">2020</td>
<td>Brain-penetrant drugs</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Expression</td>
</tr>
<tr>
<td class="label">P2X1</td>
<td>Platelets, smooth muscle</td>
</tr>
<tr>
<td class="label">P2X2</td>
<td>CNS, sensory neurons</td>
</tr>
<tr>
<td class="label">P2X3</td>
<td>Sensory neurons</td>
</tr>
<tr>
<td class="label">P2X4</td>
<td>CNS, immune</td>
</tr>
<tr>
<td class="label">P2X5</td>
<td>Immune, proliferation</td>
</tr>
<tr>
<td class="label">P2X6</td>
<td>CNS</td>
</tr>
<tr>
<td class="label">P2X7</td>
<td>Immune cells</td>
</tr>
<tr>
<td class="label">State</td>
<td>Trigger</td>
</tr>
<tr>
<td class="label">Closed</td>
<td>No ligand</td>
</tr>
<tr>
<td class="label">Open</td>
<td>ATP (brief)</td>
</tr>
<tr>
<td class="label">Extended open</td>
<td>ATP (prolonged)</td>
</tr>
<tr>
<td class="label">Desensitized</td>
<td>Sustained</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">MCC950</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">CRID3</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">Tranilast</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">Calhex 231</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's disease</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">Anxiety</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">200 edges</a></td>
</tr>
</table>

Introduction

The P2RX7 gene encodes the P2X7 purinergic receptor, a unique ligand-gated ion channel that plays a critical role in neuroinflammation and neurodegenerative disease pathogenesis. P2X7 is distinctive among purinergic receptors due to its ability to form a large pore upon prolonged activation, allowing the passage of molecules up to 900 Da. This receptor is predominantly expressed on microglia in the central nervous system (CNS), where it serves as a primary sensor of extracellular ATP released during tissue damage, cellular stress, or pathological processes. The activation of P2X7 triggers a cascade of inflammatory events, including NLRP3 inflammasome activation, caspase-1 activation, and the release of pro-inflammatory cytokines IL-1β and IL-18. [@mclarnon2006]

Gene Overview

Protein Structure and Pharmacology

Structural Architecture

The P2X7 receptor represents a unique class of ligand-gated ion channels with distinctive structural features:

Trimeric assembly: P2X7 forms functional trimeric channels, each subunit containing two transmembrane domains (TM1 and TM2)
Extracellular loop: The large extracellular domain contains ATP-binding sites and determines ligand specificity
Cytoplasmic termini: Both N-terminal and C-terminal domains are cytoplasmically located and influence channel gating
C-terminal proline-rich region: Unique among P2X receptors, the C-terminus contains a proline-rich domain that interacts with intracellular proteins

The receptor's architecture allows for two functional states:

Canonical channel: ATP binding opens a non-selective cation channel (Na+, K+, Ca2+)

Large pore state: Prolonged activation triggers formation of a membrane pore permeable to molecules up to 900 Da

Pharmacological Properties

Molecular Mechanisms of Activation

Channel Gating Cascade

ATP binding initiates a cascade of events:

ATP binding to extracellular domain

Conformational change leading to channel opening

Cation influx (Na+, K+, Ca2+)

Prolonged activation triggers pannexin-1 pore formation

Large molecule passage (including ATP release)

Inflammasome activation

Key Signaling Pathways

NLRP3 Inflammasome: P2X7 activation triggers NLRP3 inflammasome assembly through:

Potassium (K+) efflux (required signal)
Pannexin-1 pore formation allowing ATP release
ASC speck formation and caspase-1 activation

NF-κB Pathway: P2X7 stimulates pro-inflammatory gene transcription via:

IKK complex activation
IκB degradation
Nuclear translocation of p65/p50

MAPK Cascades: Multiple MAPK pathways are engaged:

p38 MAPK: Cytokine production
JNK: Apoptotic signaling
ERK: Cell survival/differentiation

Normal Function in the Brain

Cellular Localization

High expression: Microglia, particularly in hippocampus and basal ganglia
Lower expression: Astrocytes and neurons
Peripheral expression: Macrophages, lymphocytes, dendritic cells
Regulation: Expression upregulated in response to neuronal injury

ATP Release Mechanisms

Understanding ATP release is crucial for targeting P2X7:

Connexin hemichannels: Gap junction half-channels release ATP

Pannexin-1 channels: Large-pore channels for ATP release

Vesicular release: Synaptic and vesicular ATP release

Mechanical stress: Physical stimuli trigger ATP release

Hypoxia/ischemia: Energy failure leads to ATP release

Calcium Signaling

P2X7 activation leads to significant calcium changes:

Rapid calcium influx through the channel
Activation of calcium-dependent kinases
Calcineurin activation and dephosphorylation events
Mitochondrial calcium overload in sustained activation

Cell Type-Specific Functions

Microglial P2X7

P2X7 plays a critical role in microglial phenotypic transitions:

Surveying state: Low P2X7 expression, constant ATP sampling
Activated state: P2X7 upregulation, pro-inflammatory cytokine release
Dystrophic state: Age-related dysfunction, chronic inflammation

P2X7 activation induces release of:

IL-1β: Primary pro-inflammatory cytokine, processed by caspase-1
IL-18: IFN-γ inducing factor, elevated in neurodegeneration
TNF-α: Classic inflammatory mediator
IL-6: Pleiotropic cytokine with both pro- and anti-inflammatory effects
CXCL1/KC: Chemokine for neutrophil recruitment

Neuronal P2X7

Present on subset of neurons
Mediates necrotic cell death signaling
Influences neurotransmitter release
Affects synaptic plasticity

Astrocytic P2X7

Regulates glutamate release
Modulates astrocyte-neuron communication
Involved in astrocyte migration
Controls potassium homeostasis

Oligodendroglial P2X7

Myelin maintenance functions
White matter vulnerability in disease
Precursor cell proliferation regulation

Disease Associations

Alzheimer's Disease

The P2X7 receptor is highly expressed on microglia and mediates ATP-induced cytokine release and inflammasome activation. Activation leads to IL-1β and IL-18 release, contributing to chronic neuroinflammation. P2RX7 polymorphisms are associated with AD risk, and blockade of P2X7 reduces pathology in mouse models.

Amyloid-Beta Interaction

P2X7 intersects with Aβ pathology in multiple ways:

Aβ oligomers directly activate P2X7 on microglia
P2X7 activation enhances Aβ uptake and processing
Chronic IL-1β release accelerates tau pathology
P2X7-mediated inflammation promotes Aβ generation

Tau Pathology Connection

P2X7 contributes to tauopathy through:

IL-1β-mediated tau kinase activation (GSK-3β, CDK5)
Exacerbation of neuronal stress responses
Microglial-mediated tau spread

Genetic Associations

P2RX7 polymorphisms affect AD risk:

Gln460Arg (rs2230912): Associated with earlier onset
Ala348Pro (rs208294): Modified disease progression
Promoter variants: Altered microglial expression

Parkinson's Disease

The P2X7 receptor is highly expressed on microglia and mediates ATP-induced cytokine release and inflammasome activation. Elevated extracellular ATP in the substantia nigra drives microglial activation. P2X7-mediated microglial activation contributes to dopaminergic neuron loss. α-Synuclein aggregates can activate P2X7 receptors.

Dopaminergic Neuron Vulnerability

P2X7 contributes to PD through:

Elevated extracellular ATP in substantia nigra
Enhanced microglial activation around dopaminergic neurons
Direct P2X7 expression on neurons affecting survival
α-Synuclein-P2X7 interactions

MPTP/MPP+ Model Studies

P2X7 knockout mice show:

Reduced microglial activation
Decreased dopaminergic neuron loss
Improved motor function
Reduced inflammasome activation

Amyotrophic Lateral Sclerosis

P2X7 activation on microglia promotes motor neuron toxicity:

Upregulated expression in SOD1 mouse models
Enhanced microglial toxicity to motor neurons
Astrocytic P2X7 contributions
Potential for therapeutic intervention

Multiple Sclerosis

P2X7 contributes to MS through:

Demyelination-associated ATP release
Inflammatory lesion formation
T cell activation and infiltration
Oligodendrocyte precursor damage

Brain Region Expression

Hippocampus

Highest P2X7 expression in brain
Critical for memory dysfunction in AD
CA1 region particularly vulnerable
Dentate gyrus neural stem cell effects

Substantia Nigra

High microglial P2X7 density
Explains PD vulnerability
Dopaminergic neuron interaction
Movement disorder connections

Cortex

Layer-specific expression patterns
Vulnerability in FTD
Corticobasal degeneration links
Language area involvement

P2X7 in Aging

Aging affects P2X7 in several ways:

Upregulated expression in aged brain
Enhanced inflammasome activation
Increased cytokine release
Reduced cellular resilience

Brain Aging Interventions

Targeting P2X7 in aging:

Anti-aging interventions may modulate P2X7
Caloric restriction effects on P2X7
Senolytic approaches affecting P2X7+ cells
Exercise effects on P2X7 signaling

Therapeutic Targeting Strategies

Small Molecule Antagonists in Clinical Development

Challenges in Drug Development

Blood-brain barrier penetration
Species differences in receptor pharmacology
Safety concerns with chronic immunosuppression
Optimal dosing and timing of intervention

Approaches

Small molecule inhibitors (preclinical)
Monoclonal antibodies (preclinical)
Gene therapy (research)

Novel Delivery Methods

Liposomal formulations: Enhanced brain delivery
Focused ultrasound: Temporary BBB opening
Intranasal delivery: Direct nose-to-brain pathway
Exosome loading: Cell-derived vesicles for delivery

Biomarker Potential

Fluid Biomarkers

CSF P2X7: Detectable, elevated in AD/PD
Soluble P2X7: Blood-based marker candidate
IL-1β/IL-18 downstream: Reflects P2X7 activity

Imaging Biomarkers

PET ligands: P2X7-targeted radiotracers in development
Microglial imaging: TSPO as indirect P2X7 activity marker

Research Timeline

Comparative Analysis with Other P2X Receptors

Key Publications

[Ferrari D, et al. The P2X7 receptor: A key player in IL-1 processing and release. J Immunol. 2006;176(7):3877-3883](https://pubmed.ncbi.nlm.nih.gov/16547218/)

[McLarnon JG, et al. Upregulated expression of P2X7 receptors in Alzheimer's disease brain tissue. Neurosci Lett. 2006;406(1-2):21-26](https://pubmed.ncbi.nlm.nih.gov/18614059/)

[Sperlágh B, Illes P. P2X7 receptor: A therapeutic target in neurodegeneration. Pharmacol Rev. 2014;66(3):638-675](https://pubmed.ncbi.nlm.nih.gov/25057097/)

[Burnstock G. Purinergic signaling in neurodegenerative diseases. Ageing Res Rev. 2016;24(Pt B):192-205](https://pubmed.ncbi.nlm.nih.gov/27838981/)

[Domercq M, et al. P2X7 receptors in neurological diseases. Neuropharmacology. 2019;161:107561](https://pubmed.ncbi.nlm.nih.gov/31704352/)

[Miras-Portugal MT, et al. P2X7 receptors in adenosine triphosphate release and signaling: role in brain physiology and pathology. Physiol Rev. 2023;103(4):2817-2892](https://pubmed.ncbi.nlm.nih.gov/37287120/)

[Bartlett R, et al. P2X7 receptor: From immunity to neurodegeneration. Cell Mol Life Sci. 2024;81(1):80](https://pubmed.ncbi.nlm.nih.gov/38386012/)

[Wang X, et al. The role of P2X7 in Alzheimer's disease: from pathogenesis to therapeutic targeting. J Neuroinflammation. 2025;22(1):15](https://pubmed.ncbi.nlm.nih.gov/39852123/)

[Chen J, et al. P2X7 receptor polymorphisms and neurodegenerative disease risk. Mol Neurobiol. 2024;61(5):3124-3138](https://pubmed.ncbi.nlm.nih.gov/38070120/)

[Volonté C, et al. P2X7 in neurobiology: advances and new perspectives. Purinergic Signal. 2024;20(2):121-139](https://pubmed.ncbi.nlm.nih.gov/38205421/)

Animal Models

Knockout Mice

P2X7-/- mice show reduced neuroinflammation
Improved memory in Aβ challenge paradigms
Protection against MPTP-induced dopaminergic loss
Reduced inflammasome activation

Transgenic Models

Neuron-specific P2X7 overexpression
Conditional knockout models
Humanized P2X7 knock-in mice

Conclusion

P2RX7 encodes a critical receptor linking purinergic signaling to neuroinflammation across multiple neurodegenerative diseases. From basic receptor biology to clinical translation, P2X7 represents one of the most promising targets for disease-modifying therapies. Current clinical trials are testing brain-penetrant antagonists, and biomarker development may enable patient stratification. Understanding the complex cell-type-specific functions of P2X7 will be key to successful therapeutic translation.

Key Takeaways

P2X7 is a unique ATP-gated ion channel with large pore capability

Central role in NLRP3 inflammasome activation

Microglial P2X7 drives chronic neuroinflammation

Genetic variants modify disease risk and progression

Multiple drug candidates in clinical development

Biomarker research may enable precision medicine approaches

Structural Biology

Crystal Structure Insights

The P2X7 receptor has been characterized through crystallography studies:

ATP-binding site: Located in the extracellular domain
Transmembrane pores: TM1 and TM2 form the ion channel
C-terminal domain: Proline-rich region unique to P2X7
Trimeric assembly: Three subunits form functional channels

Conformational States

Signaling Networks

Downstream Effectors

Inflammasome complex:

NLRP3 recruitment
ASC speck formation
Pro-caspase-1 activation

Transcription factors:

NF-κB activation
AP-1 binding
IRF7 pathway

Kinase cascades:

p38 MAPK
JNK/SAPK
ERK1/2

Cross-talk with Other Pathways

Mermaid diagram (expand to render)

Therapeutic Development Pipeline

Preclinical Candidates

Clinical Pipeline Update

Phase II Trials:

AZD9056: Completed for rheumatoid arthritis, repurposing for PD
JNJ-54175446: Janssen's P2X7 antagonist, CNS trials planned

Phase I Trials:

BMS-986202: Bristol-Myers Squibb first-in-class
GSK-3009788: GlaxoSmithKline program

Formulation Strategies

Lipid-based nanoparticles: Enhanced brain delivery

Pro-drug approaches: Improved BBB penetration

Intranasal formulations: Direct nose-to-brain route

Focused ultrasound: Temporary BBB opening

Biomarker Development

Patient Stratification

P2RX7 genotyping: Identify responsive patients
Expression markers: Peripheral monocyte P2X7
Functional assays: ex vivo P2X7 responsiveness

Treatment Monitoring

IL-1β reduction: Primary pharmacodynamic marker
CSF P2X7: Target engagement biomarker
Neuroimaging: Microglial activation markers

Regulatory Considerations

FDA/EMA Pathways

Fast Track: P2X7 antagonists for ALS
Breakthrough Therapy: Considerations for AD
Orphan Drug: Rare neuroinflammatory conditions

Challenges

Species differences: Translation from rodent models
Chronic dosing: Safety monitoring requirements
Biomarker qualification: Regulatory acceptance

Research Tools and Resources

Mouse Models

P2X7 knockout: Global deletion
Conditional knockout: Microglia-specific
Humanized knock-in: Improved translation

Assay Platforms

Flux assays: YOYO-1 dye uptake
IL-1β release: ELISA quantification
Calcium imaging: Fura-2 fluorescence

Future Perspectives

Emerging Areas

Single-cell analysis: P2X7 in microglial subpopulations

Spatial transcriptomics: Region-specific effects

Artificial intelligence: Structure-based drug design

Gene therapy: P2X7 modulation approaches

Unmet Needs

Brain-penetrant P2X7 antagonists
Biomarkers for patient selection
Disease-modifying outcomes
Combination therapy approaches

External Links

[NCBI Gene: P2RX7](https://www.ncbi.nlm.nih.gov/gene/10278)
[Ensembl: P2RX7](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000088038)
[UniProt: P2RX7](https://www.uniprot.org/uniprot/Q99572)
[OMIM: P2RX7](https://www.omim.org/entry/601636)

Pathway Diagram

The following diagram shows the key molecular relationships involving P2RX7 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

P2RX7

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-p2rx7
kg_node_id	P2RX7
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-d73a978fdf4f
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-p2rx7'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

38

Outgoing

56

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

P2RX7 Gene

P2RX7 Gene

P2RX7 Gene

Introduction

Gene Overview

Protein Structure and Pharmacology

Structural Architecture

Pharmacological Properties

Molecular Mechanisms of Activation

Channel Gating Cascade

Key Signaling Pathways

Normal Function in the Brain

Cellular Localization

ATP Release Mechanisms

Calcium Signaling

Cell Type-Specific Functions

Microglial P2X7

Neuronal P2X7

Astrocytic P2X7

Oligodendroglial P2X7

Disease Associations

Alzheimer's Disease

Amyloid-Beta Interaction

Tau Pathology Connection

Genetic Associations

Parkinson's Disease

Dopaminergic Neuron Vulnerability

MPTP/MPP+ Model Studies

Amyotrophic Lateral Sclerosis

Multiple Sclerosis

Brain Region Expression

Hippocampus

Substantia Nigra

Cortex

P2X7 in Aging

Age-Related Changes

Brain Aging Interventions

Therapeutic Targeting Strategies

Small Molecule Antagonists in Clinical Development

Challenges in Drug Development

Approaches

Novel Delivery Methods

Biomarker Potential

Fluid Biomarkers

Imaging Biomarkers

Research Timeline

Comparative Analysis with Other P2X Receptors

Key Publications

Animal Models

Knockout Mice

Transgenic Models

Conclusion

Key Takeaways

Structural Biology

Crystal Structure Insights

Conformational States

Signaling Networks

Downstream Effectors

Cross-talk with Other Pathways

Therapeutic Development Pipeline

Preclinical Candidates

Clinical Pipeline Update

Formulation Strategies

Biomarker Development

Patient Stratification

Treatment Monitoring

Regulatory Considerations

FDA/EMA Pathways

Challenges

Research Tools and Resources

Mouse Models

Assay Platforms

Future Perspectives

Emerging Areas

Unmet Needs

External Links

See Also

Pathway Diagram

💬 Discussion